Affibody to Participate in Upcoming Healthcare Investor Conferences

2026-08-27 14:00:00

Stockholm, Sweden, August 27, 2026. Affibody AB (“Affibody”), a clinical stage radiopharmaceutical company developing next generation Radioligand Therapies (RLTs), today announced participation in two upcoming investor conferences, delivering an update on clinical data from the ongoing Phase 1 study evaluating the RLT candidate, ABY-271, in patients with HER2-positive metastatic breast cancer.

Morgan Stanley 24th Annual Global Healthcare Conference (New York City)

Presentation and 1x1 Investor Meetings
Tuesday, September 15

4th Annual Oppenheimer Targeted Radiopharmaceutical Therapies Summit (New York City)

1x1 Investor Meetings
Thursday, September 17

About Affibody

Affibody is a clinical stage radiopharmaceutical company developing next generation Radioligand Therapies (RLTs) designed to deliver highly selective tumor targeting across a wide range of cancers. Leveraging decades of innovation in Affibody^® molecule discovery and engineering, together with deep understanding of the RLT field, the company is advancing a novel pipeline focused on oncology indications with high unmet medical need. Affibody’s lead RLT candidate, ABY-271, is currently being evaluated in a first-in-human clinical study in HER2-positive metastatic breast cancer.

The Affibody^® platform has also demonstrated clinical value in immunology and inflammation, with multiple programs being advanced through strategic partnerships.

Affibody’s main shareholder, Patricia Industries, is a part of Investor AB.

Further information can be found at: www.affibody.com.